ZENBEXUS triplet shows superior PFS in relapsed and refractory multiple myeloma – BMS
Bristol Myers Squibb announced positive topline results from the Phase 3 EXCALIBER-RRMM study, evaluating ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone (ZDd) in 800 patients with multiple… read more.


